nodes	percent_of_prediction	percent_of_DWPC	metapath
Crizotinib—ALK—brain cancer	0.526	1	CbGaD
Crizotinib—Disease progression—Carmustine—brain cancer	0.00368	0.0338	CcSEcCtD
Crizotinib—Hepatotoxicity—Lomustine—brain cancer	0.00262	0.0241	CcSEcCtD
Crizotinib—Balance disorder—Procarbazine—brain cancer	0.00235	0.0216	CcSEcCtD
Crizotinib—Febrile neutropenia—Procarbazine—brain cancer	0.00214	0.0196	CcSEcCtD
Crizotinib—CASK—Teniposide—Etoposide—brain cancer	0.00179	0.532	CbGdCrCtD
Crizotinib—Febrile neutropenia—Hydroxyurea—brain cancer	0.00165	0.0152	CcSEcCtD
Crizotinib—Disorder sight—Temozolomide—brain cancer	0.00163	0.015	CcSEcCtD
Crizotinib—Visual disturbance—Lomustine—brain cancer	0.00155	0.0142	CcSEcCtD
Crizotinib—Lymphopenia—Temozolomide—brain cancer	0.00152	0.0139	CcSEcCtD
Crizotinib—Febrile neutropenia—Carmustine—brain cancer	0.00134	0.0123	CcSEcCtD
Crizotinib—Transaminases increased—Carmustine—brain cancer	0.00132	0.0121	CcSEcCtD
Crizotinib—Visual acuity reduced—Temozolomide—brain cancer	0.00131	0.012	CcSEcCtD
Crizotinib—Febrile neutropenia—Temozolomide—brain cancer	0.00129	0.0119	CcSEcCtD
Crizotinib—Hepatotoxicity—Hydroxyurea—brain cancer	0.00129	0.0118	CcSEcCtD
Crizotinib—Photophobia—Procarbazine—brain cancer	0.00121	0.0111	CcSEcCtD
Crizotinib—Neuropathy—Procarbazine—brain cancer	0.00121	0.0111	CcSEcCtD
Crizotinib—Burning sensation—Carmustine—brain cancer	0.00116	0.0106	CcSEcCtD
Crizotinib—Interstitial lung disease—Carmustine—brain cancer	0.00114	0.0104	CcSEcCtD
Crizotinib—Interstitial lung disease—Temozolomide—brain cancer	0.0011	0.0101	CcSEcCtD
Crizotinib—Hepatic function abnormal—Procarbazine—brain cancer	0.00107	0.0098	CcSEcCtD
Crizotinib—Hepatotoxicity—Carmustine—brain cancer	0.00104	0.00956	CcSEcCtD
Crizotinib—Febrile neutropenia—Etoposide—brain cancer	0.00103	0.00948	CcSEcCtD
Crizotinib—Abscess—Carmustine—brain cancer	0.00102	0.00933	CcSEcCtD
Crizotinib—Hepatotoxicity—Temozolomide—brain cancer	0.00101	0.00923	CcSEcCtD
Crizotinib—Visual impairment—Lomustine—brain cancer	0.00098	0.00899	CcSEcCtD
Crizotinib—Gamma-glutamyltransferase increased—Temozolomide—brain cancer	0.000944	0.00867	CcSEcCtD
Crizotinib—Diplopia—Procarbazine—brain cancer	0.000933	0.00856	CcSEcCtD
Crizotinib—PLK4—Teniposide—Etoposide—brain cancer	0.000886	0.263	CbGdCrCtD
Crizotinib—Interstitial lung disease—Etoposide—brain cancer	0.000878	0.00806	CcSEcCtD
Crizotinib—Gait disturbance—Carmustine—brain cancer	0.000824	0.00756	CcSEcCtD
Crizotinib—Infection—Carboplatin—brain cancer	0.00082	0.00753	CcSEcCtD
Crizotinib—Hepatotoxicity—Etoposide—brain cancer	0.000805	0.00739	CcSEcCtD
Crizotinib—Pulmonary embolism—Carmustine—brain cancer	0.000804	0.00738	CcSEcCtD
Crizotinib—Hepatic failure—Hydroxyurea—brain cancer	0.000803	0.00737	CcSEcCtD
Crizotinib—Gait disturbance—Temozolomide—brain cancer	0.000796	0.00731	CcSEcCtD
Crizotinib—Leukopenia—Lomustine—brain cancer	0.000792	0.00727	CcSEcCtD
Crizotinib—Respiratory failure—Temozolomide—brain cancer	0.000791	0.00726	CcSEcCtD
Crizotinib—Phosphatase alkaline increased—Temozolomide—brain cancer	0.000777	0.00713	CcSEcCtD
Crizotinib—Pulmonary embolism—Temozolomide—brain cancer	0.000777	0.00713	CcSEcCtD
Crizotinib—Neuropathy—Carmustine—brain cancer	0.000755	0.00693	CcSEcCtD
Crizotinib—Neuropathy—Temozolomide—brain cancer	0.000729	0.00669	CcSEcCtD
Crizotinib—Pneumonia—Procarbazine—brain cancer	0.000723	0.00664	CcSEcCtD
Crizotinib—Infection—Lomustine—brain cancer	0.000717	0.00658	CcSEcCtD
Crizotinib—Neuropathy peripheral—Procarbazine—brain cancer	0.000705	0.00647	CcSEcCtD
Crizotinib—Sepsis—Carmustine—brain cancer	0.000698	0.0064	CcSEcCtD
Crizotinib—Face oedema—Hydroxyurea—brain cancer	0.000697	0.0064	CcSEcCtD
Crizotinib—AURKA—Teniposide—Etoposide—brain cancer	0.000694	0.206	CbGdCrCtD
Crizotinib—Body temperature increased—Carboplatin—brain cancer	0.000653	0.00599	CcSEcCtD
Crizotinib—Blood alkaline phosphatase increased—Temozolomide—brain cancer	0.000648	0.00595	CcSEcCtD
Crizotinib—Decreased appetite—Lomustine—brain cancer	0.000628	0.00576	CcSEcCtD
Crizotinib—Hepatic failure—Temozolomide—brain cancer	0.000628	0.00576	CcSEcCtD
Crizotinib—Phosphatase alkaline increased—Etoposide—brain cancer	0.000622	0.00571	CcSEcCtD
Crizotinib—Neuropathy—Etoposide—brain cancer	0.000584	0.00536	CcSEcCtD
Crizotinib—Diplopia—Carmustine—brain cancer	0.000584	0.00536	CcSEcCtD
Crizotinib—Neutropenia—Hydroxyurea—brain cancer	0.000583	0.00535	CcSEcCtD
Crizotinib—Arrhythmia—Procarbazine—brain cancer	0.000576	0.00529	CcSEcCtD
Crizotinib—Body temperature increased—Lomustine—brain cancer	0.000571	0.00524	CcSEcCtD
Crizotinib—Diplopia—Temozolomide—brain cancer	0.000564	0.00518	CcSEcCtD
Crizotinib—Face oedema—Carmustine—brain cancer	0.000563	0.00517	CcSEcCtD
Crizotinib—Infestation NOS—Hydroxyurea—brain cancer	0.000556	0.00511	CcSEcCtD
Crizotinib—Infestation—Hydroxyurea—brain cancer	0.000556	0.00511	CcSEcCtD
Crizotinib—Neuropathy peripheral—Hydroxyurea—brain cancer	0.000545	0.005	CcSEcCtD
Crizotinib—Face oedema—Temozolomide—brain cancer	0.000544	0.005	CcSEcCtD
Crizotinib—Sepsis—Etoposide—brain cancer	0.000539	0.00495	CcSEcCtD
Crizotinib—Hypokalaemia—Carmustine—brain cancer	0.000531	0.00487	CcSEcCtD
Crizotinib—Hepatobiliary disease—Hydroxyurea—brain cancer	0.000526	0.00483	CcSEcCtD
Crizotinib—Anaemia—Procarbazine—brain cancer	0.000519	0.00476	CcSEcCtD
Crizotinib—Blood alkaline phosphatase increased—Etoposide—brain cancer	0.000519	0.00476	CcSEcCtD
Crizotinib—Muscular weakness—Carmustine—brain cancer	0.000515	0.00472	CcSEcCtD
Crizotinib—Hypokalaemia—Temozolomide—brain cancer	0.000513	0.00471	CcSEcCtD
Crizotinib—Aspartate aminotransferase increased—Temozolomide—brain cancer	0.000508	0.00466	CcSEcCtD
Crizotinib—Syncope—Procarbazine—brain cancer	0.000504	0.00462	CcSEcCtD
Crizotinib—Leukopenia—Procarbazine—brain cancer	0.000503	0.00461	CcSEcCtD
Crizotinib—Alanine aminotransferase increased—Temozolomide—brain cancer	0.000497	0.00456	CcSEcCtD
Crizotinib—Muscular weakness—Temozolomide—brain cancer	0.000497	0.00456	CcSEcCtD
Crizotinib—Loss of consciousness—Procarbazine—brain cancer	0.000494	0.00453	CcSEcCtD
Crizotinib—Neutropenia—Carmustine—brain cancer	0.000472	0.00433	CcSEcCtD
Crizotinib—Vomiting—Lomustine—brain cancer	0.000459	0.00421	CcSEcCtD
Crizotinib—Oedema—Procarbazine—brain cancer	0.000458	0.00421	CcSEcCtD
Crizotinib—Neutropenia—Temozolomide—brain cancer	0.000456	0.00418	CcSEcCtD
Crizotinib—Infection—Procarbazine—brain cancer	0.000455	0.00418	CcSEcCtD
Crizotinib—Upper respiratory tract infection—Temozolomide—brain cancer	0.000453	0.00416	CcSEcCtD
Crizotinib—Pneumonia—Carmustine—brain cancer	0.000452	0.00415	CcSEcCtD
Crizotinib—Shock—Procarbazine—brain cancer	0.000451	0.00414	CcSEcCtD
Crizotinib—Weight decreased—Temozolomide—brain cancer	0.000441	0.00405	CcSEcCtD
Crizotinib—Neuropathy peripheral—Carmustine—brain cancer	0.000441	0.00405	CcSEcCtD
Crizotinib—Pneumonia—Temozolomide—brain cancer	0.000437	0.00401	CcSEcCtD
Crizotinib—Infestation NOS—Temozolomide—brain cancer	0.000435	0.00399	CcSEcCtD
Crizotinib—Infestation—Temozolomide—brain cancer	0.000435	0.00399	CcSEcCtD
Crizotinib—Nausea—Lomustine—brain cancer	0.000429	0.00394	CcSEcCtD
Crizotinib—Neuropathy peripheral—Temozolomide—brain cancer	0.000426	0.00391	CcSEcCtD
Crizotinib—Paraesthesia—Procarbazine—brain cancer	0.000412	0.00378	CcSEcCtD
Crizotinib—Hepatobiliary disease—Temozolomide—brain cancer	0.000411	0.00377	CcSEcCtD
Crizotinib—Anaemia—Hydroxyurea—brain cancer	0.000402	0.00369	CcSEcCtD
Crizotinib—Hypoaesthesia—Carmustine—brain cancer	0.000402	0.00369	CcSEcCtD
Crizotinib—Decreased appetite—Procarbazine—brain cancer	0.000399	0.00366	CcSEcCtD
Crizotinib—Alanine aminotransferase increased—Etoposide—brain cancer	0.000398	0.00365	CcSEcCtD
Crizotinib—Oedema peripheral—Carmustine—brain cancer	0.000398	0.00365	CcSEcCtD
Crizotinib—Fatigue—Procarbazine—brain cancer	0.000395	0.00363	CcSEcCtD
Crizotinib—Constipation—Procarbazine—brain cancer	0.000392	0.0036	CcSEcCtD
Crizotinib—Leukopenia—Hydroxyurea—brain cancer	0.000389	0.00357	CcSEcCtD
Crizotinib—Visual impairment—Carmustine—brain cancer	0.000389	0.00357	CcSEcCtD
Crizotinib—Hypoaesthesia—Temozolomide—brain cancer	0.000388	0.00356	CcSEcCtD
Crizotinib—Urinary tract disorder—Temozolomide—brain cancer	0.000385	0.00354	CcSEcCtD
Crizotinib—Oedema peripheral—Temozolomide—brain cancer	0.000384	0.00353	CcSEcCtD
Crizotinib—Urethral disorder—Temozolomide—brain cancer	0.000382	0.00351	CcSEcCtD
Crizotinib—Eye disorder—Carmustine—brain cancer	0.000377	0.00346	CcSEcCtD
Crizotinib—Visual impairment—Temozolomide—brain cancer	0.000376	0.00345	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—brain cancer	0.000368	0.00337	CcSEcCtD
Crizotinib—Neutropenia—Etoposide—brain cancer	0.000365	0.00335	CcSEcCtD
Crizotinib—Eye disorder—Temozolomide—brain cancer	0.000365	0.00335	CcSEcCtD
Crizotinib—Body temperature increased—Procarbazine—brain cancer	0.000362	0.00333	CcSEcCtD
Crizotinib—Cardiac disorder—Temozolomide—brain cancer	0.000362	0.00332	CcSEcCtD
Crizotinib—Arrhythmia—Carmustine—brain cancer	0.000361	0.00331	CcSEcCtD
Crizotinib—Oedema—Hydroxyurea—brain cancer	0.000355	0.00326	CcSEcCtD
Crizotinib—Infection—Hydroxyurea—brain cancer	0.000352	0.00323	CcSEcCtD
Crizotinib—Mediastinal disorder—Temozolomide—brain cancer	0.000352	0.00323	CcSEcCtD
Crizotinib—Malnutrition—Carmustine—brain cancer	0.000351	0.00323	CcSEcCtD
Crizotinib—Pneumonia—Etoposide—brain cancer	0.00035	0.00321	CcSEcCtD
Crizotinib—Nervous system disorder—Hydroxyurea—brain cancer	0.000348	0.00319	CcSEcCtD
Crizotinib—Infestation NOS—Etoposide—brain cancer	0.000348	0.00319	CcSEcCtD
Crizotinib—Infestation—Etoposide—brain cancer	0.000348	0.00319	CcSEcCtD
Crizotinib—Skin disorder—Hydroxyurea—brain cancer	0.000345	0.00316	CcSEcCtD
Crizotinib—Neuropathy peripheral—Etoposide—brain cancer	0.000341	0.00313	CcSEcCtD
Crizotinib—Malnutrition—Temozolomide—brain cancer	0.00034	0.00312	CcSEcCtD
Crizotinib—Dysgeusia—Temozolomide—brain cancer	0.000333	0.00305	CcSEcCtD
Crizotinib—Vision blurred—Carmustine—brain cancer	0.000331	0.00304	CcSEcCtD
Crizotinib—Asthenia—Procarbazine—brain cancer	0.000329	0.00302	CcSEcCtD
Crizotinib—Hepatobiliary disease—Etoposide—brain cancer	0.000329	0.00302	CcSEcCtD
Crizotinib—Anaemia—Carmustine—brain cancer	0.000325	0.00298	CcSEcCtD
Crizotinib—Vision blurred—Temozolomide—brain cancer	0.00032	0.00294	CcSEcCtD
Crizotinib—Dyspnoea—Hydroxyurea—brain cancer	0.000316	0.0029	CcSEcCtD
Crizotinib—Leukopenia—Carmustine—brain cancer	0.000315	0.00289	CcSEcCtD
Crizotinib—Anaemia—Temozolomide—brain cancer	0.000314	0.00288	CcSEcCtD
Crizotinib—Diarrhoea—Procarbazine—brain cancer	0.000314	0.00288	CcSEcCtD
Crizotinib—Dyspepsia—Hydroxyurea—brain cancer	0.000312	0.00287	CcSEcCtD
Crizotinib—Hypoaesthesia—Etoposide—brain cancer	0.000311	0.00285	CcSEcCtD
Crizotinib—Decreased appetite—Hydroxyurea—brain cancer	0.000308	0.00283	CcSEcCtD
Crizotinib—Urinary tract disorder—Etoposide—brain cancer	0.000308	0.00283	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Hydroxyurea—brain cancer	0.000306	0.00281	CcSEcCtD
Crizotinib—Urethral disorder—Etoposide—brain cancer	0.000306	0.00281	CcSEcCtD
Crizotinib—Fatigue—Hydroxyurea—brain cancer	0.000306	0.00281	CcSEcCtD
Crizotinib—Leukopenia—Temozolomide—brain cancer	0.000304	0.00279	CcSEcCtD
Crizotinib—Constipation—Hydroxyurea—brain cancer	0.000303	0.00278	CcSEcCtD
Crizotinib—Dizziness—Procarbazine—brain cancer	0.000303	0.00278	CcSEcCtD
Crizotinib—Eye disorder—Etoposide—brain cancer	0.000292	0.00268	CcSEcCtD
Crizotinib—Vomiting—Procarbazine—brain cancer	0.000291	0.00268	CcSEcCtD
Crizotinib—Cardiac disorder—Etoposide—brain cancer	0.00029	0.00266	CcSEcCtD
Crizotinib—Rash—Procarbazine—brain cancer	0.000289	0.00265	CcSEcCtD
Crizotinib—Dermatitis—Procarbazine—brain cancer	0.000289	0.00265	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—brain cancer	0.000287	0.00264	CcSEcCtD
Crizotinib—Oedema—Carmustine—brain cancer	0.000287	0.00263	CcSEcCtD
Crizotinib—Infection—Carmustine—brain cancer	0.000285	0.00262	CcSEcCtD
Crizotinib—Mediastinal disorder—Etoposide—brain cancer	0.000281	0.00258	CcSEcCtD
Crizotinib—Body temperature increased—Hydroxyurea—brain cancer	0.00028	0.00257	CcSEcCtD
Crizotinib—Oedema—Temozolomide—brain cancer	0.000277	0.00254	CcSEcCtD
Crizotinib—Infection—Temozolomide—brain cancer	0.000275	0.00253	CcSEcCtD
Crizotinib—Nausea—Procarbazine—brain cancer	0.000272	0.0025	CcSEcCtD
Crizotinib—Nervous system disorder—Temozolomide—brain cancer	0.000272	0.00249	CcSEcCtD
Crizotinib—Skin disorder—Temozolomide—brain cancer	0.000269	0.00247	CcSEcCtD
Crizotinib—Dysgeusia—Etoposide—brain cancer	0.000266	0.00244	CcSEcCtD
Crizotinib—Paraesthesia—Carmustine—brain cancer	0.000258	0.00236	CcSEcCtD
Crizotinib—Dyspnoea—Carmustine—brain cancer	0.000256	0.00235	CcSEcCtD
Crizotinib—Asthenia—Hydroxyurea—brain cancer	0.000255	0.00234	CcSEcCtD
Crizotinib—TAOK2—brain—brain cancer	0.000253	0.00162	CbGeAlD
Crizotinib—EPHB4—pituitary gland—brain cancer	0.000253	0.00162	CbGeAlD
Crizotinib—MAP4K2—cerebellum—brain cancer	0.000252	0.00161	CbGeAlD
Crizotinib—STK35—endocrine gland—brain cancer	0.000252	0.00161	CbGeAlD
Crizotinib—JAK2—pituitary gland—brain cancer	0.000251	0.0016	CbGeAlD
Crizotinib—Anaemia—Etoposide—brain cancer	0.000251	0.00231	CcSEcCtD
Crizotinib—Decreased appetite—Carmustine—brain cancer	0.000249	0.00229	CcSEcCtD
Crizotinib—Paraesthesia—Temozolomide—brain cancer	0.000249	0.00228	CcSEcCtD
Crizotinib—STK3—cerebellum—brain cancer	0.000249	0.00159	CbGeAlD
Crizotinib—TIE1—cerebellum—brain cancer	0.000249	0.00159	CbGeAlD
Crizotinib—STK35—head—brain cancer	0.000248	0.00159	CbGeAlD
Crizotinib—EPHA2—pituitary gland—brain cancer	0.000248	0.00159	CbGeAlD
Crizotinib—MAP3K3—gonad—brain cancer	0.000248	0.00159	CbGeAlD
Crizotinib—MAP4K5—gonad—brain cancer	0.000248	0.00159	CbGeAlD
Crizotinib—AURKA—central nervous system—brain cancer	0.000248	0.00158	CbGeAlD
Crizotinib—Gastrointestinal disorder—Carmustine—brain cancer	0.000248	0.00227	CcSEcCtD
Crizotinib—Dyspnoea—Temozolomide—brain cancer	0.000247	0.00227	CcSEcCtD
Crizotinib—SLK—medulla oblongata—brain cancer	0.000246	0.00157	CbGeAlD
Crizotinib—TESK1—central nervous system—brain cancer	0.000246	0.00157	CbGeAlD
Crizotinib—Constipation—Carmustine—brain cancer	0.000245	0.00225	CcSEcCtD
Crizotinib—TBK1—midbrain—brain cancer	0.000245	0.00157	CbGeAlD
Crizotinib—PTK2—midbrain—brain cancer	0.000245	0.00157	CbGeAlD
Crizotinib—EPHB4—medulla oblongata—brain cancer	0.000244	0.00156	CbGeAlD
Crizotinib—EPHA3—brain—brain cancer	0.000244	0.00156	CbGeAlD
Crizotinib—ACVR1B—brain—brain cancer	0.000244	0.00156	CbGeAlD
Crizotinib—Dyspepsia—Temozolomide—brain cancer	0.000244	0.00224	CcSEcCtD
Crizotinib—TYK2—midbrain—brain cancer	0.000244	0.00156	CbGeAlD
Crizotinib—Leukopenia—Etoposide—brain cancer	0.000243	0.00223	CcSEcCtD
Crizotinib—Diarrhoea—Hydroxyurea—brain cancer	0.000243	0.00223	CcSEcCtD
Crizotinib—JAK2—medulla oblongata—brain cancer	0.000242	0.00155	CbGeAlD
Crizotinib—BMP2K—endocrine gland—brain cancer	0.000242	0.00155	CbGeAlD
Crizotinib—TEK—pituitary gland—brain cancer	0.000242	0.00155	CbGeAlD
Crizotinib—MAP4K5—pituitary gland—brain cancer	0.000242	0.00155	CbGeAlD
Crizotinib—MAP3K3—pituitary gland—brain cancer	0.000242	0.00155	CbGeAlD
Crizotinib—Decreased appetite—Temozolomide—brain cancer	0.000241	0.00221	CcSEcCtD
Crizotinib—IRAK1—midbrain—brain cancer	0.00024	0.00154	CbGeAlD
Crizotinib—TESK1—cerebellum—brain cancer	0.00024	0.00153	CbGeAlD
Crizotinib—Gastrointestinal disorder—Temozolomide—brain cancer	0.000239	0.0022	CcSEcCtD
Crizotinib—PTK2—spinal cord—brain cancer	0.000239	0.00153	CbGeAlD
Crizotinib—TBK1—spinal cord—brain cancer	0.000239	0.00153	CbGeAlD
Crizotinib—MERTK—central nervous system—brain cancer	0.000239	0.00153	CbGeAlD
Crizotinib—BMP2K—head—brain cancer	0.000239	0.00153	CbGeAlD
Crizotinib—Fatigue—Temozolomide—brain cancer	0.000239	0.00219	CcSEcCtD
Crizotinib—Loss of consciousness—Etoposide—brain cancer	0.000239	0.00219	CcSEcCtD
Crizotinib—TYK2—spinal cord—brain cancer	0.000238	0.00152	CbGeAlD
Crizotinib—CSF1R—telencephalon—brain cancer	0.000237	0.00151	CbGeAlD
Crizotinib—Constipation—Temozolomide—brain cancer	0.000237	0.00218	CcSEcCtD
Crizotinib—RPS6KB1—midbrain—brain cancer	0.000236	0.00151	CbGeAlD
Crizotinib—Dizziness—Hydroxyurea—brain cancer	0.000235	0.00215	CcSEcCtD
Crizotinib—LIMK2—central nervous system—brain cancer	0.000234	0.00149	CbGeAlD
Crizotinib—PTK2B—endocrine gland—brain cancer	0.000234	0.00149	CbGeAlD
Crizotinib—MERTK—cerebellum—brain cancer	0.000234	0.00149	CbGeAlD
Crizotinib—TEK—medulla oblongata—brain cancer	0.000234	0.00149	CbGeAlD
Crizotinib—MAP4K5—medulla oblongata—brain cancer	0.000234	0.00149	CbGeAlD
Crizotinib—MAP3K3—medulla oblongata—brain cancer	0.000234	0.00149	CbGeAlD
Crizotinib—AXL—midbrain—brain cancer	0.000233	0.00149	CbGeAlD
Crizotinib—JAK3—brain—brain cancer	0.000233	0.00149	CbGeAlD
Crizotinib—EPHA6—brain—brain cancer	0.000233	0.00149	CbGeAlD
Crizotinib—RIPK2—endocrine gland—brain cancer	0.000232	0.00148	CbGeAlD
Crizotinib—DCLK1—brain—brain cancer	0.000231	0.00148	CbGeAlD
Crizotinib—MAP3K12—central nervous system—brain cancer	0.000231	0.00148	CbGeAlD
Crizotinib—ACVR1—central nervous system—brain cancer	0.000231	0.00148	CbGeAlD
Crizotinib—EPHB6—pituitary gland—brain cancer	0.000231	0.00148	CbGeAlD
Crizotinib—PTK2B—head—brain cancer	0.000231	0.00147	CbGeAlD
Crizotinib—RPS6KB1—spinal cord—brain cancer	0.00023	0.00147	CbGeAlD
Crizotinib—PLK4—brain—brain cancer	0.00023	0.00147	CbGeAlD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—brain cancer	0.00023	0.00211	CcSEcCtD
Crizotinib—YES1—gonad—brain cancer	0.000229	0.00146	CbGeAlD
Crizotinib—RIPK2—head—brain cancer	0.000229	0.00146	CbGeAlD
Crizotinib—STK4—brain—brain cancer	0.000229	0.00146	CbGeAlD
Crizotinib—LIMK2—cerebellum—brain cancer	0.000229	0.00146	CbGeAlD
Crizotinib—AXL—spinal cord—brain cancer	0.000228	0.00145	CbGeAlD
Crizotinib—NUAK2—cerebellum—brain cancer	0.000228	0.00145	CbGeAlD
Crizotinib—STK10—gonad—brain cancer	0.000227	0.00145	CbGeAlD
Crizotinib—Body temperature increased—Carmustine—brain cancer	0.000227	0.00208	CcSEcCtD
Crizotinib—STK35—central nervous system—brain cancer	0.000227	0.00145	CbGeAlD
Crizotinib—MAP3K12—cerebellum—brain cancer	0.000226	0.00144	CbGeAlD
Crizotinib—ACVR1—cerebellum—brain cancer	0.000226	0.00144	CbGeAlD
Crizotinib—FLT3—cerebellum—brain cancer	0.000226	0.00144	CbGeAlD
Crizotinib—Vomiting—Hydroxyurea—brain cancer	0.000226	0.00207	CcSEcCtD
Crizotinib—SLK—midbrain—brain cancer	0.000225	0.00144	CbGeAlD
Crizotinib—EPHA4—endocrine gland—brain cancer	0.000224	0.00143	CbGeAlD
Crizotinib—Rash—Hydroxyurea—brain cancer	0.000224	0.00205	CcSEcCtD
Crizotinib—YES1—pituitary gland—brain cancer	0.000224	0.00143	CbGeAlD
Crizotinib—Dermatitis—Hydroxyurea—brain cancer	0.000224	0.00205	CcSEcCtD
Crizotinib—EPHB6—medulla oblongata—brain cancer	0.000223	0.00143	CbGeAlD
Crizotinib—EPHB4—midbrain—brain cancer	0.000223	0.00143	CbGeAlD
Crizotinib—STK35—cerebellum—brain cancer	0.000222	0.00142	CbGeAlD
Crizotinib—EPHA4—head—brain cancer	0.000221	0.00141	CbGeAlD
Crizotinib—TAOK3—pituitary gland—brain cancer	0.000221	0.00141	CbGeAlD
Crizotinib—SRC—gonad—brain cancer	0.00022	0.00141	CbGeAlD
Crizotinib—Infection—Etoposide—brain cancer	0.00022	0.00202	CcSEcCtD
Crizotinib—MAP3K2—endocrine gland—brain cancer	0.00022	0.0014	CbGeAlD
Crizotinib—SLK—spinal cord—brain cancer	0.000219	0.0014	CbGeAlD
Crizotinib—Body temperature increased—Temozolomide—brain cancer	0.000219	0.00201	CcSEcCtD
Crizotinib—BMP2K—central nervous system—brain cancer	0.000218	0.00139	CbGeAlD
Crizotinib—EPHB4—spinal cord—brain cancer	0.000218	0.00139	CbGeAlD
Crizotinib—MAP3K2—head—brain cancer	0.000217	0.00139	CbGeAlD
Crizotinib—JAK2—spinal cord—brain cancer	0.000216	0.00138	CbGeAlD
Crizotinib—ALK—brain—brain cancer	0.000216	0.00138	CbGeAlD
Crizotinib—TYRO3—brain—brain cancer	0.000216	0.00138	CbGeAlD
Crizotinib—EPHA5—brain—brain cancer	0.000216	0.00138	CbGeAlD
Crizotinib—FER—brain—brain cancer	0.000216	0.00138	CbGeAlD
Crizotinib—ABL2—cerebellum—brain cancer	0.000216	0.00138	CbGeAlD
Crizotinib—YES1—medulla oblongata—brain cancer	0.000216	0.00138	CbGeAlD
Crizotinib—Skin disorder—Etoposide—brain cancer	0.000215	0.00198	CcSEcCtD
Crizotinib—TBK1—endocrine gland—brain cancer	0.000215	0.00138	CbGeAlD
Crizotinib—PTK2—endocrine gland—brain cancer	0.000215	0.00138	CbGeAlD
Crizotinib—LYN—brain—brain cancer	0.000215	0.00137	CbGeAlD
Crizotinib—TYK2—endocrine gland—brain cancer	0.000214	0.00137	CbGeAlD
Crizotinib—TNK1—brain—brain cancer	0.000214	0.00137	CbGeAlD
Crizotinib—MAP3K3—midbrain—brain cancer	0.000214	0.00136	CbGeAlD
Crizotinib—TEK—midbrain—brain cancer	0.000214	0.00136	CbGeAlD
Crizotinib—MAP4K5—midbrain—brain cancer	0.000214	0.00136	CbGeAlD
Crizotinib—BMP2K—cerebellum—brain cancer	0.000213	0.00136	CbGeAlD
Crizotinib—TAOK3—medulla oblongata—brain cancer	0.000213	0.00136	CbGeAlD
Crizotinib—TBK1—head—brain cancer	0.000213	0.00136	CbGeAlD
Crizotinib—PTK2—head—brain cancer	0.000213	0.00136	CbGeAlD
Crizotinib—MAP4K1—brain—brain cancer	0.000212	0.00135	CbGeAlD
Crizotinib—MAP3K19—brain—brain cancer	0.000212	0.00135	CbGeAlD
Crizotinib—BMPR1B—brain—brain cancer	0.000212	0.00135	CbGeAlD
Crizotinib—ABL1—brainstem—brain cancer	0.000211	0.00135	CbGeAlD
Crizotinib—TYK2—head—brain cancer	0.000211	0.00135	CbGeAlD
Crizotinib—Nausea—Hydroxyurea—brain cancer	0.000211	0.00193	CcSEcCtD
Crizotinib—PTK2B—central nervous system—brain cancer	0.000211	0.00135	CbGeAlD
Crizotinib—MAP3K3—spinal cord—brain cancer	0.000208	0.00133	CbGeAlD
Crizotinib—TEK—spinal cord—brain cancer	0.000208	0.00133	CbGeAlD
Crizotinib—MAP4K5—spinal cord—brain cancer	0.000208	0.00133	CbGeAlD
Crizotinib—TNK2—brain—brain cancer	0.000208	0.00133	CbGeAlD
Crizotinib—IGF1R—brain—brain cancer	0.000208	0.00133	CbGeAlD
Crizotinib—RPS6KB1—endocrine gland—brain cancer	0.000207	0.00132	CbGeAlD
Crizotinib—PTK2B—cerebellum—brain cancer	0.000206	0.00132	CbGeAlD
Crizotinib—FGR—endocrine gland—brain cancer	0.000206	0.00132	CbGeAlD
Crizotinib—Asthenia—Carmustine—brain cancer	0.000206	0.00189	CcSEcCtD
Crizotinib—AXL—endocrine gland—brain cancer	0.000205	0.00131	CbGeAlD
Crizotinib—MAP4K2—brain—brain cancer	0.000205	0.00131	CbGeAlD
Crizotinib—RPS6KB1—head—brain cancer	0.000205	0.00131	CbGeAlD
Crizotinib—RIPK2—cerebellum—brain cancer	0.000204	0.0013	CbGeAlD
Crizotinib—EPHB6—midbrain—brain cancer	0.000204	0.0013	CbGeAlD
Crizotinib—FGR—head—brain cancer	0.000203	0.0013	CbGeAlD
Crizotinib—AXL—head—brain cancer	0.000202	0.00129	CbGeAlD
Crizotinib—EPHA4—central nervous system—brain cancer	0.000202	0.00129	CbGeAlD
Crizotinib—STK3—brain—brain cancer	0.000202	0.00129	CbGeAlD
Crizotinib—TIE1—brain—brain cancer	0.000202	0.00129	CbGeAlD
Crizotinib—Paraesthesia—Etoposide—brain cancer	0.000199	0.00183	CcSEcCtD
Crizotinib—EPHB6—spinal cord—brain cancer	0.000199	0.00127	CbGeAlD
Crizotinib—Asthenia—Temozolomide—brain cancer	0.000199	0.00183	CcSEcCtD
Crizotinib—MAP3K2—central nervous system—brain cancer	0.000198	0.00127	CbGeAlD
Crizotinib—CSF1R—gonad—brain cancer	0.000198	0.00126	CbGeAlD
Crizotinib—Dyspnoea—Etoposide—brain cancer	0.000198	0.00181	CcSEcCtD
Crizotinib—EPHA4—cerebellum—brain cancer	0.000197	0.00126	CbGeAlD
Crizotinib—YES1—midbrain—brain cancer	0.000197	0.00126	CbGeAlD
Crizotinib—AURKA—brain—brain cancer	0.000197	0.00126	CbGeAlD
Crizotinib—Diarrhoea—Carmustine—brain cancer	0.000196	0.0018	CcSEcCtD
Crizotinib—EPHB4—endocrine gland—brain cancer	0.000196	0.00125	CbGeAlD
Crizotinib—TESK1—brain—brain cancer	0.000195	0.00125	CbGeAlD
Crizotinib—TAOK3—midbrain—brain cancer	0.000195	0.00124	CbGeAlD
Crizotinib—JAK2—endocrine gland—brain cancer	0.000195	0.00124	CbGeAlD
Crizotinib—PTK2—central nervous system—brain cancer	0.000194	0.00124	CbGeAlD
Crizotinib—TBK1—central nervous system—brain cancer	0.000194	0.00124	CbGeAlD
Crizotinib—MAP3K2—cerebellum—brain cancer	0.000194	0.00124	CbGeAlD
Crizotinib—CSF1R—pituitary gland—brain cancer	0.000193	0.00123	CbGeAlD
Crizotinib—Decreased appetite—Etoposide—brain cancer	0.000193	0.00177	CcSEcCtD
Crizotinib—TYK2—central nervous system—brain cancer	0.000193	0.00123	CbGeAlD
Crizotinib—YES1—spinal cord—brain cancer	0.000192	0.00123	CbGeAlD
Crizotinib—EPHA2—endocrine gland—brain cancer	0.000192	0.00123	CbGeAlD
Crizotinib—JAK2—head—brain cancer	0.000192	0.00123	CbGeAlD
Crizotinib—Gastrointestinal disorder—Etoposide—brain cancer	0.000191	0.00176	CcSEcCtD
Crizotinib—Fatigue—Etoposide—brain cancer	0.000191	0.00175	CcSEcCtD
Crizotinib—TAOK3—spinal cord—brain cancer	0.00019	0.00121	CbGeAlD
Crizotinib—MERTK—brain—brain cancer	0.00019	0.00121	CbGeAlD
Crizotinib—EPHA2—head—brain cancer	0.00019	0.00121	CbGeAlD
Crizotinib—Dizziness—Carmustine—brain cancer	0.00019	0.00174	CcSEcCtD
Crizotinib—Constipation—Etoposide—brain cancer	0.00019	0.00174	CcSEcCtD
Crizotinib—PTK2—cerebellum—brain cancer	0.00019	0.00121	CbGeAlD
Crizotinib—TBK1—cerebellum—brain cancer	0.00019	0.00121	CbGeAlD
Crizotinib—Diarrhoea—Temozolomide—brain cancer	0.00019	0.00174	CcSEcCtD
Crizotinib—TYK2—cerebellum—brain cancer	0.000188	0.0012	CbGeAlD
Crizotinib—TEK—endocrine gland—brain cancer	0.000188	0.0012	CbGeAlD
Crizotinib—MAP4K5—endocrine gland—brain cancer	0.000188	0.0012	CbGeAlD
Crizotinib—MAP3K3—endocrine gland—brain cancer	0.000188	0.0012	CbGeAlD
Crizotinib—ABL1—telencephalon—brain cancer	0.000187	0.0012	CbGeAlD
Crizotinib—RPS6KB1—central nervous system—brain cancer	0.000187	0.00119	CbGeAlD
Crizotinib—CSF1R—medulla oblongata—brain cancer	0.000186	0.00119	CbGeAlD
Crizotinib—IRAK1—cerebellum—brain cancer	0.000186	0.00119	CbGeAlD
Crizotinib—LIMK2—brain—brain cancer	0.000186	0.00119	CbGeAlD
Crizotinib—FGR—central nervous system—brain cancer	0.000186	0.00119	CbGeAlD
Crizotinib—MAP4K5—head—brain cancer	0.000185	0.00118	CbGeAlD
Crizotinib—TEK—head—brain cancer	0.000185	0.00118	CbGeAlD
Crizotinib—MAP3K3—head—brain cancer	0.000185	0.00118	CbGeAlD
Crizotinib—SRC—spinal cord—brain cancer	0.000185	0.00118	CbGeAlD
Crizotinib—NUAK2—brain—brain cancer	0.000185	0.00118	CbGeAlD
Crizotinib—AXL—central nervous system—brain cancer	0.000185	0.00118	CbGeAlD
Crizotinib—MAP3K12—brain—brain cancer	0.000184	0.00117	CbGeAlD
Crizotinib—ACVR1—brain—brain cancer	0.000184	0.00117	CbGeAlD
Crizotinib—Dizziness—Temozolomide—brain cancer	0.000183	0.00168	CcSEcCtD
Crizotinib—RPS6KB1—cerebellum—brain cancer	0.000182	0.00117	CbGeAlD
Crizotinib—Vomiting—Carmustine—brain cancer	0.000182	0.00167	CcSEcCtD
Crizotinib—Rash—Carmustine—brain cancer	0.000181	0.00166	CcSEcCtD
Crizotinib—Dermatitis—Carmustine—brain cancer	0.000181	0.00166	CcSEcCtD
Crizotinib—AXL—cerebellum—brain cancer	0.000181	0.00115	CbGeAlD
Crizotinib—STK35—brain—brain cancer	0.00018	0.00115	CbGeAlD
Crizotinib—EPHB6—head—brain cancer	0.000177	0.00113	CbGeAlD
Crizotinib—Vomiting—Temozolomide—brain cancer	0.000176	0.00162	CcSEcCtD
Crizotinib—ABL2—brain—brain cancer	0.000175	0.00112	CbGeAlD
Crizotinib—JAK2—central nervous system—brain cancer	0.000175	0.00112	CbGeAlD
Crizotinib—Body temperature increased—Etoposide—brain cancer	0.000175	0.00161	CcSEcCtD
Crizotinib—Rash—Temozolomide—brain cancer	0.000175	0.0016	CcSEcCtD
Crizotinib—Dermatitis—Temozolomide—brain cancer	0.000175	0.0016	CcSEcCtD
Crizotinib—SLK—cerebellum—brain cancer	0.000174	0.00111	CbGeAlD
Crizotinib—EPHA2—central nervous system—brain cancer	0.000173	0.00111	CbGeAlD
Crizotinib—BMP2K—brain—brain cancer	0.000173	0.00111	CbGeAlD
Crizotinib—YES1—endocrine gland—brain cancer	0.000173	0.00111	CbGeAlD
Crizotinib—EPHB4—cerebellum—brain cancer	0.000173	0.0011	CbGeAlD
Crizotinib—STK10—endocrine gland—brain cancer	0.000172	0.0011	CbGeAlD
Crizotinib—JAK2—cerebellum—brain cancer	0.000171	0.00109	CbGeAlD
Crizotinib—YES1—head—brain cancer	0.000171	0.00109	CbGeAlD
Crizotinib—TAOK3—endocrine gland—brain cancer	0.000171	0.00109	CbGeAlD
Crizotinib—Nausea—Carmustine—brain cancer	0.00017	0.00156	CcSEcCtD
Crizotinib—CSF1R—midbrain—brain cancer	0.00017	0.00109	CbGeAlD
Crizotinib—STK10—head—brain cancer	0.000169	0.00108	CbGeAlD
Crizotinib—MAP4K5—central nervous system—brain cancer	0.000169	0.00108	CbGeAlD
Crizotinib—TEK—central nervous system—brain cancer	0.000169	0.00108	CbGeAlD
Crizotinib—MAP3K3—central nervous system—brain cancer	0.000169	0.00108	CbGeAlD
Crizotinib—TAOK3—head—brain cancer	0.000169	0.00108	CbGeAlD
Crizotinib—PTK2B—brain—brain cancer	0.000167	0.00107	CbGeAlD
Crizotinib—SRC—endocrine gland—brain cancer	0.000167	0.00106	CbGeAlD
Crizotinib—CSF1R—spinal cord—brain cancer	0.000166	0.00106	CbGeAlD
Crizotinib—RIPK2—brain—brain cancer	0.000166	0.00106	CbGeAlD
Crizotinib—TEK—cerebellum—brain cancer	0.000165	0.00106	CbGeAlD
Crizotinib—MAP3K3—cerebellum—brain cancer	0.000165	0.00106	CbGeAlD
Crizotinib—MAP4K5—cerebellum—brain cancer	0.000165	0.00106	CbGeAlD
Crizotinib—Nausea—Temozolomide—brain cancer	0.000165	0.00151	CcSEcCtD
Crizotinib—SRC—head—brain cancer	0.000165	0.00105	CbGeAlD
Crizotinib—EPHB6—central nervous system—brain cancer	0.000162	0.00103	CbGeAlD
Crizotinib—EPHA4—brain—brain cancer	0.00016	0.00102	CbGeAlD
Crizotinib—Asthenia—Etoposide—brain cancer	0.000159	0.00146	CcSEcCtD
Crizotinib—EPHB6—cerebellum—brain cancer	0.000158	0.00101	CbGeAlD
Crizotinib—MAP3K2—brain—brain cancer	0.000157	0.001	CbGeAlD
Crizotinib—ABL1—gonad—brain cancer	0.000156	0.000999	CbGeAlD
Crizotinib—YES1—central nervous system—brain cancer	0.000156	0.000997	CbGeAlD
Crizotinib—STK10—central nervous system—brain cancer	0.000155	0.000988	CbGeAlD
Crizotinib—TAOK3—central nervous system—brain cancer	0.000154	0.000984	CbGeAlD
Crizotinib—PTK2—brain—brain cancer	0.000154	0.000984	CbGeAlD
Crizotinib—TBK1—brain—brain cancer	0.000154	0.000984	CbGeAlD
Crizotinib—TYK2—brain—brain cancer	0.000153	0.000977	CbGeAlD
Crizotinib—ABL1—pituitary gland—brain cancer	0.000153	0.000975	CbGeAlD
Crizotinib—YES1—cerebellum—brain cancer	0.000153	0.000974	CbGeAlD
Crizotinib—Diarrhoea—Etoposide—brain cancer	0.000152	0.00139	CcSEcCtD
Crizotinib—STK10—cerebellum—brain cancer	0.000151	0.000966	CbGeAlD
Crizotinib—IRAK1—brain—brain cancer	0.000151	0.000965	CbGeAlD
Crizotinib—TAOK3—cerebellum—brain cancer	0.000151	0.000962	CbGeAlD
Crizotinib—SRC—central nervous system—brain cancer	0.00015	0.000959	CbGeAlD
Crizotinib—CSF1R—endocrine gland—brain cancer	0.00015	0.000955	CbGeAlD
Crizotinib—RPS6KB1—brain—brain cancer	0.000148	0.000947	CbGeAlD
Crizotinib—CSF1R—head—brain cancer	0.000148	0.000943	CbGeAlD
Crizotinib—ABL1—medulla oblongata—brain cancer	0.000147	0.000941	CbGeAlD
Crizotinib—FGR—brain—brain cancer	0.000147	0.000941	CbGeAlD
Crizotinib—SRC—cerebellum—brain cancer	0.000147	0.000937	CbGeAlD
Crizotinib—AXL—brain—brain cancer	0.000147	0.000937	CbGeAlD
Crizotinib—Dizziness—Etoposide—brain cancer	0.000147	0.00135	CcSEcCtD
Crizotinib—SLK—brain—brain cancer	0.000141	0.000902	CbGeAlD
Crizotinib—Vomiting—Etoposide—brain cancer	0.000141	0.00129	CcSEcCtD
Crizotinib—EPHB4—brain—brain cancer	0.00014	0.000895	CbGeAlD
Crizotinib—Rash—Etoposide—brain cancer	0.00014	0.00128	CcSEcCtD
Crizotinib—Dermatitis—Etoposide—brain cancer	0.00014	0.00128	CcSEcCtD
Crizotinib—JAK2—brain—brain cancer	0.000139	0.000889	CbGeAlD
Crizotinib—EPHA2—brain—brain cancer	0.000138	0.000878	CbGeAlD
Crizotinib—CSF1R—central nervous system—brain cancer	0.000135	0.000861	CbGeAlD
Crizotinib—ABL1—midbrain—brain cancer	0.000135	0.00086	CbGeAlD
Crizotinib—TEK—brain—brain cancer	0.000134	0.000857	CbGeAlD
Crizotinib—MAP4K5—brain—brain cancer	0.000134	0.000857	CbGeAlD
Crizotinib—MAP3K3—brain—brain cancer	0.000134	0.000857	CbGeAlD
Crizotinib—CSF1R—cerebellum—brain cancer	0.000132	0.000842	CbGeAlD
Crizotinib—Nausea—Etoposide—brain cancer	0.000132	0.00121	CcSEcCtD
Crizotinib—ABL1—spinal cord—brain cancer	0.000131	0.000839	CbGeAlD
Crizotinib—EPHB6—brain—brain cancer	0.000128	0.000819	CbGeAlD
Crizotinib—YES1—brain—brain cancer	0.000124	0.000791	CbGeAlD
Crizotinib—STK10—brain—brain cancer	0.000123	0.000784	CbGeAlD
Crizotinib—TAOK3—brain—brain cancer	0.000122	0.000781	CbGeAlD
Crizotinib—ABCB1—blood vessel—brain cancer	0.00012	0.000768	CbGeAlD
Crizotinib—SRC—brain—brain cancer	0.000119	0.000761	CbGeAlD
Crizotinib—ABL1—endocrine gland—brain cancer	0.000118	0.000755	CbGeAlD
Crizotinib—ABL1—head—brain cancer	0.000117	0.000746	CbGeAlD
Crizotinib—CSF1R—brain—brain cancer	0.000107	0.000684	CbGeAlD
Crizotinib—ABL1—central nervous system—brain cancer	0.000107	0.000681	CbGeAlD
Crizotinib—ABL1—cerebellum—brain cancer	0.000104	0.000665	CbGeAlD
Crizotinib—ABL1—brain—brain cancer	8.46e-05	0.00054	CbGeAlD
Crizotinib—CYP3A5—endocrine gland—brain cancer	6.92e-05	0.000442	CbGeAlD
Crizotinib—ABCB1—telencephalon—brain cancer	5.83e-05	0.000372	CbGeAlD
Crizotinib—CYP3A4—endocrine gland—brain cancer	5.19e-05	0.000332	CbGeAlD
Crizotinib—ABCB1—gonad—brain cancer	4.87e-05	0.000311	CbGeAlD
Crizotinib—ABCB1—pituitary gland—brain cancer	4.75e-05	0.000303	CbGeAlD
Crizotinib—CYP3A4—central nervous system—brain cancer	4.68e-05	0.000299	CbGeAlD
Crizotinib—ABCB1—medulla oblongata—brain cancer	4.58e-05	0.000293	CbGeAlD
Crizotinib—ABCB1—midbrain—brain cancer	4.19e-05	0.000267	CbGeAlD
Crizotinib—ABCB1—spinal cord—brain cancer	4.08e-05	0.000261	CbGeAlD
Crizotinib—ABCB1—endocrine gland—brain cancer	3.68e-05	0.000235	CbGeAlD
Crizotinib—ABCB1—head—brain cancer	3.63e-05	0.000232	CbGeAlD
Crizotinib—ABCB1—central nervous system—brain cancer	3.31e-05	0.000212	CbGeAlD
Crizotinib—ABCB1—cerebellum—brain cancer	3.24e-05	0.000207	CbGeAlD
Crizotinib—ABCB1—brain—brain cancer	2.63e-05	0.000168	CbGeAlD
Crizotinib—IRAK1—Immune System—CTNNB1—brain cancer	3.88e-06	1.9e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—PDGFRA—brain cancer	3.88e-06	1.9e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—APC—brain cancer	3.88e-06	1.9e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—RELA—brain cancer	3.88e-06	1.89e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—CCND1—brain cancer	3.88e-06	1.89e-05	CbGpPWpGaD
Crizotinib—LYN—Hemostasis—TP53—brain cancer	3.87e-06	1.89e-05	CbGpPWpGaD
Crizotinib—ABL1—Hemostasis—TP53—brain cancer	3.86e-06	1.88e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—ERBB2—brain cancer	3.85e-06	1.88e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—IRS2—brain cancer	3.85e-06	1.88e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—CTNNB1—brain cancer	3.84e-06	1.87e-05	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—CTNNB1—brain cancer	3.8e-06	1.86e-05	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—VEGFA—brain cancer	3.79e-06	1.85e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—CTNNB1—brain cancer	3.77e-06	1.84e-05	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—STAT3—brain cancer	3.75e-06	1.83e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—VAV1—brain cancer	3.75e-06	1.83e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—PDGFRA—brain cancer	3.75e-06	1.83e-05	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—VEGFA—brain cancer	3.72e-06	1.82e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—RELA—brain cancer	3.71e-06	1.81e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—PIK3CG—brain cancer	3.7e-06	1.8e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—APC—brain cancer	3.7e-06	1.8e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—IRS2—brain cancer	3.69e-06	1.8e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—ERBB2—brain cancer	3.69e-06	1.8e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—HES1—brain cancer	3.68e-06	1.8e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—SPP1—brain cancer	3.64e-06	1.78e-05	CbGpPWpGaD
Crizotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—brain cancer	3.63e-06	1.77e-05	CbGpPWpGaD
Crizotinib—JAK2—Hemostasis—TP53—brain cancer	3.63e-06	1.77e-05	CbGpPWpGaD
Crizotinib—PTK2—Immune System—STAT3—brain cancer	3.62e-06	1.77e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—RELA—brain cancer	3.6e-06	1.76e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—PIK3CG—brain cancer	3.59e-06	1.75e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—APC—brain cancer	3.59e-06	1.75e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—ERBB2—brain cancer	3.58e-06	1.75e-05	CbGpPWpGaD
Crizotinib—YES1—Immune System—STAT3—brain cancer	3.57e-06	1.74e-05	CbGpPWpGaD
Crizotinib—JAK2—GPCR downstream signaling—IL2—brain cancer	3.57e-06	1.74e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—IL2—brain cancer	3.54e-06	1.73e-05	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—TP53—brain cancer	3.53e-06	1.72e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—RELA—brain cancer	3.51e-06	1.71e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—PDGFRA—brain cancer	3.51e-06	1.71e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—RELA—brain cancer	3.5e-06	1.71e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—IL2—brain cancer	3.49e-06	1.71e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—ERBB2—brain cancer	3.49e-06	1.7e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—NOTCH2—brain cancer	3.48e-06	1.7e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—CTNNB1—brain cancer	3.48e-06	1.7e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—ERBB2—brain cancer	3.47e-06	1.7e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CYP2C9—brain cancer	3.47e-06	1.69e-05	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—TP53—brain cancer	3.46e-06	1.69e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—CCND1—brain cancer	3.46e-06	1.69e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—CTNNB1—brain cancer	3.42e-06	1.67e-05	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—EGFR—brain cancer	3.41e-06	1.67e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—IRS2—brain cancer	3.41e-06	1.66e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—CCND1—brain cancer	3.41e-06	1.66e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—SPP1—brain cancer	3.41e-06	1.66e-05	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—EGFR—brain cancer	3.4e-06	1.66e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—APC—brain cancer	3.4e-06	1.66e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—STAT3—brain cancer	3.39e-06	1.65e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—VEGFA—brain cancer	3.38e-06	1.65e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—CTNNB1—brain cancer	3.37e-06	1.65e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—STAT3—brain cancer	3.35e-06	1.63e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—IL2—brain cancer	3.34e-06	1.63e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—VAV1—brain cancer	3.32e-06	1.62e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—IRS2—brain cancer	3.29e-06	1.61e-05	CbGpPWpGaD
Crizotinib—PTK2—Immune System—EGFR—brain cancer	3.29e-06	1.61e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—STAT3—brain cancer	3.29e-06	1.6e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—RELA—brain cancer	3.29e-06	1.6e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—EGFR—brain cancer	3.27e-06	1.6e-05	CbGpPWpGaD
Crizotinib—LCK—Adaptive Immune System—EGFR—brain cancer	3.27e-06	1.6e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—ERBB2—brain cancer	3.27e-06	1.59e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—CCND1—brain cancer	3.26e-06	1.59e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—ENO2—brain cancer	3.25e-06	1.59e-05	CbGpPWpGaD
Crizotinib—YES1—Immune System—EGFR—brain cancer	3.24e-06	1.58e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—IL2—brain cancer	3.24e-06	1.58e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—IL2—brain cancer	3.24e-06	1.58e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—CTNNB1—brain cancer	3.23e-06	1.58e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—HES1—brain cancer	3.23e-06	1.58e-05	CbGpPWpGaD
Crizotinib—LCK—Hemostasis—TP53—brain cancer	3.18e-06	1.55e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—IL2—brain cancer	3.16e-06	1.54e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—CCND1—brain cancer	3.16e-06	1.54e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—IL2—brain cancer	3.15e-06	1.54e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—CTNNB1—brain cancer	3.13e-06	1.53e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—MYC—brain cancer	3.11e-06	1.52e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—RELA—brain cancer	3.09e-06	1.51e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—IRS2—brain cancer	3.08e-06	1.5e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—EGFR—brain cancer	3.08e-06	1.5e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—PDGFRA—brain cancer	3.07e-06	1.5e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—ERBB2—brain cancer	3.07e-06	1.5e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—CTNNB1—brain cancer	3.05e-06	1.49e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—RELA—brain cancer	3.05e-06	1.49e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—EGFR—brain cancer	3.04e-06	1.48e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—CTNNB1—brain cancer	3.04e-06	1.48e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—STAT3—brain cancer	3.03e-06	1.48e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—ERBB2—brain cancer	3.03e-06	1.48e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—ERBB2—brain cancer	3.02e-06	1.47e-05	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—EGFR—brain cancer	3.01e-06	1.47e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—VEGFA—brain cancer	3.01e-06	1.47e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—APC—brain cancer	3.01e-06	1.47e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—EGFR—brain cancer	2.99e-06	1.46e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—SPP1—brain cancer	2.98e-06	1.46e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—STAT3—brain cancer	2.98e-06	1.46e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—VEGFA—brain cancer	2.97e-06	1.45e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—IL2—brain cancer	2.96e-06	1.45e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—BSG—brain cancer	2.95e-06	1.44e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—STAT3—brain cancer	2.94e-06	1.44e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—APC—brain cancer	2.91e-06	1.42e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—PIK3CG—brain cancer	2.91e-06	1.42e-05	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—EGFR—brain cancer	2.89e-06	1.41e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—RELA—brain cancer	2.89e-06	1.41e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—RELA—brain cancer	2.88e-06	1.41e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—ERBB2—brain cancer	2.87e-06	1.4e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—ERBB2—brain cancer	2.86e-06	1.4e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—CTNNB1—brain cancer	2.86e-06	1.4e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—HES1—brain cancer	2.86e-06	1.39e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—VEGFA—brain cancer	2.84e-06	1.39e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—MYC—brain cancer	2.82e-06	1.38e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—STAT3—brain cancer	2.81e-06	1.37e-05	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—TP53—brain cancer	2.81e-06	1.37e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—RELA—brain cancer	2.8e-06	1.37e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—ERBB2—brain cancer	2.79e-06	1.36e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—IL2—brain cancer	2.78e-06	1.36e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—MYC—brain cancer	2.77e-06	1.35e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—EGFR—brain cancer	2.76e-06	1.35e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—VEGFA—brain cancer	2.75e-06	1.35e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—IL2—brain cancer	2.74e-06	1.34e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—MYC—brain cancer	2.73e-06	1.33e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—STAT3—brain cancer	2.73e-06	1.33e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—PDGFRA—brain cancer	2.72e-06	1.33e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—PIK3CG—brain cancer	2.72e-06	1.33e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—APC—brain cancer	2.72e-06	1.33e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—CCND1—brain cancer	2.71e-06	1.32e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—EGFR—brain cancer	2.71e-06	1.32e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—IRS2—brain cancer	2.7e-06	1.32e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—CTNNB1—brain cancer	2.68e-06	1.31e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—CCND1—brain cancer	2.67e-06	1.31e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—EGFR—brain cancer	2.67e-06	1.3e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—STAT3—brain cancer	2.66e-06	1.3e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—STAT3—brain cancer	2.65e-06	1.29e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—CTNNB1—brain cancer	2.65e-06	1.29e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—ERBB2—brain cancer	2.64e-06	1.29e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—SPP1—brain cancer	2.64e-06	1.29e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—CTNNB1—brain cancer	2.64e-06	1.29e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—MYC—brain cancer	2.61e-06	1.28e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—IL2—brain cancer	2.6e-06	1.27e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—IL2—brain cancer	2.59e-06	1.27e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—EGFR—brain cancer	2.56e-06	1.25e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—TP53—brain cancer	2.55e-06	1.25e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—RELA—brain cancer	2.55e-06	1.24e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—CCND1—brain cancer	2.54e-06	1.24e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—IDH1—brain cancer	2.54e-06	1.24e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—MYC—brain cancer	2.53e-06	1.24e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—ERBB2—brain cancer	2.53e-06	1.24e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—IL2—brain cancer	2.53e-06	1.23e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—CTNNB1—brain cancer	2.51e-06	1.23e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—CTNNB1—brain cancer	2.5e-06	1.22e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—STAT3—brain cancer	2.49e-06	1.22e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—EGFR—brain cancer	2.48e-06	1.21e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—EGFR—brain cancer	2.48e-06	1.21e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—CCND1—brain cancer	2.46e-06	1.2e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—CTNNB1—brain cancer	2.44e-06	1.19e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—EGFR—brain cancer	2.42e-06	1.18e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—EGFR—brain cancer	2.41e-06	1.18e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—IRS2—brain cancer	2.39e-06	1.17e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—PIK3CG—brain cancer	2.38e-06	1.16e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—APC—brain cancer	2.38e-06	1.16e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—VEGFA—brain cancer	2.36e-06	1.15e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—STAT3—brain cancer	2.34e-06	1.14e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—ERBB2—brain cancer	2.34e-06	1.14e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—VEGFA—brain cancer	2.33e-06	1.14e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—CTNNB1—brain cancer	2.31e-06	1.13e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—STAT3—brain cancer	2.31e-06	1.13e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—STAT3—brain cancer	2.3e-06	1.12e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—IL2—brain cancer	2.3e-06	1.12e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—TP53—brain cancer	2.28e-06	1.11e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—RELA—brain cancer	2.27e-06	1.11e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—EGFR—brain cancer	2.26e-06	1.11e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—ERBB2—brain cancer	2.26e-06	1.1e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—TP53—brain cancer	2.24e-06	1.1e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—CTNNB1—brain cancer	2.22e-06	1.08e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—VEGFA—brain cancer	2.21e-06	1.08e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—STAT3—brain cancer	2.19e-06	1.07e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—STAT3—brain cancer	2.18e-06	1.07e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—MYC—brain cancer	2.17e-06	1.06e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—TP53—brain cancer	2.15e-06	1.05e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—VEGFA—brain cancer	2.15e-06	1.05e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—MYC—brain cancer	2.14e-06	1.05e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—MYC—brain cancer	2.14e-06	1.04e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—EGFR—brain cancer	2.13e-06	1.04e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—RELA—brain cancer	2.13e-06	1.04e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—STAT3—brain cancer	2.13e-06	1.04e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—ERBB2—brain cancer	2.11e-06	1.03e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—PIK3CG—brain cancer	2.11e-06	1.03e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—APC—brain cancer	2.11e-06	1.03e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—EGFR—brain cancer	2.1e-06	1.02e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—EGFR—brain cancer	2.09e-06	1.02e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—TP53—brain cancer	2.08e-06	1.02e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—CTNNB1—brain cancer	2.05e-06	9.99e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—IL2—brain cancer	2.05e-06	9.99e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—MYC—brain cancer	2.03e-06	9.93e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—STAT3—brain cancer	2.01e-06	9.84e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—ENO2—brain cancer	2e-06	9.78e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CCND1—brain cancer	1.99e-06	9.73e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—EGFR—brain cancer	1.99e-06	9.71e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—EGFR—brain cancer	1.98e-06	9.68e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PIK3CG—brain cancer	1.98e-06	9.65e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—MYC—brain cancer	1.97e-06	9.64e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CTNNB1—brain cancer	1.97e-06	9.64e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—STAT3—brain cancer	1.93e-06	9.43e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—EGFR—brain cancer	1.93e-06	9.43e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—IL2—brain cancer	1.91e-06	9.34e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—MYC—brain cancer	1.87e-06	9.14e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CCND1—brain cancer	1.87e-06	9.11e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—RELA—brain cancer	1.86e-06	9.09e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—ERBB2—brain cancer	1.85e-06	9.03e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CTNNB1—brain cancer	1.85e-06	9.02e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—EGFR—brain cancer	1.83e-06	8.94e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—TP53—brain cancer	1.79e-06	8.72e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—STAT3—brain cancer	1.78e-06	8.71e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—TP53—brain cancer	1.76e-06	8.6e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—EGFR—brain cancer	1.76e-06	8.57e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—VEGFA—brain cancer	1.74e-06	8.49e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—STAT3—brain cancer	1.72e-06	8.4e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—IL2—brain cancer	1.68e-06	8.18e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—TP53—brain cancer	1.67e-06	8.16e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—MYC—brain cancer	1.66e-06	8.09e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—RELA—brain cancer	1.65e-06	8.05e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—ERBB2—brain cancer	1.64e-06	8e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CCND1—brain cancer	1.63e-06	7.98e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—VEGFA—brain cancer	1.63e-06	7.94e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—TP53—brain cancer	1.62e-06	7.92e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—EGFR—brain cancer	1.62e-06	7.91e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CTNNB1—brain cancer	1.62e-06	7.9e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—STAT3—brain cancer	1.61e-06	7.86e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—MYC—brain cancer	1.6e-06	7.81e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—EGFR—brain cancer	1.56e-06	7.64e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—MYC—brain cancer	1.5e-06	7.31e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PIK3CG—brain cancer	1.49e-06	7.29e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—IL2—brain cancer	1.48e-06	7.25e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—EGFR—brain cancer	1.46e-06	7.15e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CCND1—brain cancer	1.45e-06	7.06e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CTNNB1—brain cancer	1.43e-06	7e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—VEGFA—brain cancer	1.42e-06	6.96e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—STAT3—brain cancer	1.41e-06	6.89e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—TP53—brain cancer	1.31e-06	6.41e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—MYC—brain cancer	1.31e-06	6.4e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—EGFR—brain cancer	1.28e-06	6.26e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—VEGFA—brain cancer	1.26e-06	6.16e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—STAT3—brain cancer	1.25e-06	6.1e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—TP53—brain cancer	1.23e-06	6e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MYC—brain cancer	1.16e-06	5.67e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—EGFR—brain cancer	1.13e-06	5.54e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—TP53—brain cancer	1.08e-06	5.26e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—TP53—brain cancer	9.53e-07	4.65e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PIK3CG—brain cancer	9.19e-07	4.49e-06	CbGpPWpGaD
